Feature | EP Mapping and Imaging Systems | May 15, 2019 | Dave Fornell, Editor

Electromechanical Wave Imaging Can Correctly Localize Cardiac Arrhythmias

New ultrasound imaging technology can noninvasively electromap the heart prior to ablations

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.


May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial tachycardia (AT), atrial flutter (AFL), premature ventricular complexes (PVC), and accessory pathways (AP) in Wolff-Parkinson-White syndrome prior to catheter ablation. The double-blinded study for this new technology was presented as a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Diagnosis and localization of arrhythmias are critical for decision making and treatment planning prior to cardiac ablation. The 12 lead ECG is the main noninvasive tool used to localize arrhythmias, however it can be limited in specificity and subject to interobserver variability. Electromechanical Wave Imaging (EWI) is a novel, high frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm.

In this study, EWI was able to correctly predict 96% of arrhythmia locations as compared with 71% for 12-lead ECG analyses (unadjusted for arrhythmia type: OR: 11.8; 95% CI: 2.2-63.2; p=0.004; adjusted for arrhythmia type: OR: 12.1; 95% CI: 2.3-63.2; p=0.003). There was significant inter-observer variability amongst ECG reads.

Ongoing efforts include incorporating EWI isochrones into 3-D anatomical maps prior to ablation to determine whether EWI can affect clinical outcomes, said Elaine Wan, M.D., FHRS, the Esther Aboodi Assistant Professor of Medicine in Cardiology and Cardiac Electrophysiology at Columbia University Medical Center. She explained this includes reducing procedure time and radiation dose, in addition to exploring EWI with transesophageal, intracardiac, and 3-D ultrasound.

In the study, patients presenting for catheter ablation of AT, AFL, PVCs, or an AP underwent transthoracic EWI and 12 lead ECG prior to the ablation. 67 patients were consented, 12 patients were excluded due to withdrawal of consent, poor imaging or not being in the arrhythmia at time of imaging. There were 55 patients who underwent EWI (mean age 56.0±2.3 years, 71% male). Of these, 22% had WPW, 20% had PVCs, 13% had AT and 45% had AFL. Six blinded clinical electrophysiologists predicted arrhythmia origins based on ECG alone. EWI isochrone processing was blinded to all clinical data except arrhythmia type. Operating physicians were blinded to EWI isochrones. EWI and ECG predictions were compared to arrhythmia location as determined by 3-D electroanatomic mapping and ablation using a standardized 21 segment cardiac model.

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

 

 


Related Content

News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which ...

Home May 10, 2024
Home
Subscribe Now